Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia

During the last few years many Checkpoint kinase 1/2 (Chk1/Chk2) inhibitors have been developed for the treatment of different type of cancers. In this study we evaluated the efficacy of the Chk 1/2 inhibitor prexasertib mesylate monohydrate in B-/T- cell progenitor acute lymphoblastic leukemia (ALL...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Rorà, Andrea Ghelli Luserna Di, Iacobucci, Ilaria, Imbrogno, Enrica, Papayannidis, Cristina, Derenzini, Enrico, Ferrari, Anna, Guadagnuolo, Viviana, Robustelli, Valentina, Parisi, Sarah, Sartor, Chiara, Abbenante, Maria Chiara, Paolini, Stefania, Martinelli, Giovanni
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2016
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5288194/
https://ncbi.nlm.nih.gov/pubmed/27438145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10535
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller